X

Trial Profile

A Prospective Observational Study of Adult Patients Receiving DUPIXENT for Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Acronyms PROSE
Sponsors Regeneron Pharmaceuticals; Sanofi

Most Recent Events

12 Mar 2024 A 3-year Interim Results presented at the American Academy of Dermatology annual Meeting 2024
21 Mar 2023 Interim Results (n= 764) assessing Effectiveness of Dupilumab in Adult and Adolescent Patients With Atopic Dermatitis presented at the American Academy of Dermatology annual Meeting 2023
10 Jun 2022 Planned End Date changed from 9 Jun 2027 to 30 Mar 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com